Overview
Compare with Sonoma Pharmaceuticals, Inc., NEPHROS INC or Vivos Therapeutics, Inc., or pick any stock.
- TickerMDAI on Nasdaq1
- IndustrySurgical & Medical Instruments & Apparatus1
- HeadquartersDallas, Texas1
- Incorporated inDE2
- Business address2515 Mckinney Ave #1000, Dallas, Tx 752012
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
PBS contract. Completion of these contractual phases support our long-term goal of entering a federal procurement contract with BARDA.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue55¢$10.7M
- Other costs45¢$8.9M
- Income tax0¢$11.0K
Out of $19.6M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development revenue | $19.6M | $29.6M |
| Cost of revenue | -$10.7M | -$16.3M |
| Gross profit | $8.9M | $13.3M |
| General and administrative | $17.5M | $19.9M |
| Total operating costs and expenses | $17.5M | $19.9M |
| Operating loss | -$8.6M | -$6.6M |
| Net interest (expense) income | -$886.0K | $14.0K |
| Financing related costs | -$1.1M | -$3.0M |
| Amortization of debt discount | -$455.0K | |
| Change in fair value of warrant liabilities | $3.2M | -$4.6M |
| Change in fair value of notes payable | $220.0K | -$220.0K |
| Foreign exchange transaction loss, net | -$34.0K | -$43.0K |
| Other expenses, including transaction costs | -$615.0K | |
| Total other income (expense), net | $1.0M | -$8.5M |
| Loss before income taxes | -$7.6M | -$15.0M |
| Income tax provision | -$11.0K | -$114.0K |
| Net loss | -$7.6M | -$15.2M |
| Basic (in Dollars per share) | -$0.29 | -$0.85 |
| Diluted (in Dollars per share) | -$0.29 | -$0.85 |
| Basic (in Shares) | 26.5M shares | 17.9M shares |
| Diluted (in Shares) | 26.5M shares | 17.9M shares |
| Foreign currency translation adjustments | $37.0K | -$9.0K |
| Total comprehensive loss | -$7.5M | -$15.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $15.4M | $5.2M | $4.6M | |
| Accounts receivable, net | $1.3M | $2.5M | ||
| Inventory | $838.0K | $425.0K | ||
| Prepaid expenses | $821.0K | $1.3M | ||
| Other current assets | $1.1M | $746.0K | ||
| Total current assets | $19.5M | $10.1M | ||
| Property and equipment, net | $258.0K | $2.0K | ||
| Right-of-use assets | $1.4M | $2.0M | ||
| Other assets | $287.0K | |||
| Total Assets | $21.4M | $12.1M | ||
| Accounts payable | $3.0M | $4.0M | ||
| Accrued expenses | $2.3M | $3.2M | ||
| Deferred revenue | $154.0K | $960.0K | ||
| Lease liabilities, short-term | $734.0K | $201.0K | ||
| Notes payable | $2.9M | $422.0K | ||
| Notes payable at fair value | $2.4M | |||
| Warrant liabilities | $11.5M | $6.5M | ||
| Total current liabilities | $20.6M | $17.6M | ||
| Notes payable, long-term | $5.5M | |||
| Lease liabilities, long-term | $968.0K | $1.7M | ||
| Total Liabilities | $27.1M | $19.3M | ||
| Common stock ($0.0001 par value); 80,000,000 shares authorized; 30,688,895 and 22,594,877 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $3.0K | $2.0K | ||
| Additional paid-in capital | $50.0M | $41.0M | ||
| Accumulated other comprehensive income | $40.0K | $3.0K | ||
| Accumulated deficit | -$55.8M | -$48.2M | ||
| Total Stockholders Deficit | -$5.7M | -$7.3M | -$2.1M | |
| Total Liabilities and Stockholders Deficit | $21.4M | $12.1M | ||
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in Shares) | 80.0M shares | 80.0M shares | ||
| Common stock, shares issued (in Shares) | 30.7M shares | 22.6M shares | ||
| Common stock, shares outstanding (in Shares) | 30.7M shares | 22.6M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash | $15.4M | $5.2M | $4.6M | |
| Accounts receivable, net | $1.3M | $2.5M | ||
| Inventory | $838.0K | $425.0K | ||
| Prepaid expenses | $821.0K | $1.3M | ||
| Other current assets | $1.1M | $746.0K | ||
| Total current assets | $19.5M | $10.1M | ||
| Property and equipment, net | $258.0K | $2.0K | ||
| Right-of-use assets | $1.4M | $2.0M | ||
| Other assets | $287.0K | |||
| Total Assets | $21.4M | $12.1M | ||
| Accounts payable | $3.0M | $4.0M | ||
| Accrued expenses | $2.3M | $3.2M | ||
| Deferred revenue | $154.0K | $960.0K | ||
| Lease liabilities, short-term | $734.0K | $201.0K | ||
| Notes payable | $2.9M | $422.0K | ||
| Notes payable at fair value | $2.4M | |||
| Warrant liabilities | $11.5M | $6.5M | ||
| Total current liabilities | $20.6M | $17.6M | ||
| Notes payable, long-term | $5.5M | |||
| Lease liabilities, long-term | $968.0K | $1.7M | ||
| Total Liabilities | $27.1M | $19.3M | ||
| Common stock ($0.0001 par value); 80,000,000 shares authorized; 30,688,895 and 22,594,877 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $3.0K | $2.0K | ||
| Additional paid-in capital | $50.0M | $41.0M | ||
| Accumulated other comprehensive income | $40.0K | $3.0K | ||
| Accumulated deficit | -$55.8M | -$48.2M | ||
| Total Stockholders Deficit | -$5.7M | -$7.3M | -$2.1M | |
| Total Liabilities and Stockholders Deficit | $21.4M | $12.1M | ||
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in Shares) | 1.0M shares | 1.0M shares | ||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in Shares) | 80.0M shares | 80.0M shares | ||
| Common stock, shares issued (in Shares) | 30.7M shares | 22.6M shares | ||
| Common stock, shares outstanding (in Shares) | 30.7M shares | 22.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$7.6M | -$15.2M |
| Depreciation expense | $71.0K | $10.0K |
| Amortization of debt issuance costs | $454.0K | |
| Stock-based compensation | $1.1M | $1.0M |
| Amortization of right-of-use assets | $564.0K | $578.0K |
| Change in fair value of warrant liabilities | -$3.2M | $4.6M |
| Change in fair value of notes payable | -$220.0K | $220.0K |
| Costs from issuance of common stock | $372.0K | |
| Issuance of shares for borrowing related costs | $241.0K | $1.1M |
| Transaction costs allocated to Avenue Warrants, Investor Warrants, and Hudson Warrants | $704.0K | |
| Accounts receivable | $1.2M | -$159.0K |
| Inventory | -$413.0K | -$195.0K |
| Prepaid expenses | $761.0K | $163.0K |
| Other assets | -$387.0K | -$102.0K |
| Accounts payable | -$1.0M | $1.4M |
| Accrued expenses | -$869.0K | -$1.1M |
| Deferred revenue | -$806.0K | -$1.4M |
| Lease liabilities | -$528.0K | -$721.0K |
| Net cash used in operating activities | -$9.9M | -$9.2M |
| Proceeds from issuance of common stock and warrants | $10.6M | $4.1M |
| Payment of issuance costs | -$642.0K | |
| Proceeds from notes payable | $8.3M | $12.1M |
| Payment of borrowing costs | -$47.0K | |
| Proceeds from notes payable - related party | $1.0M | |
| Payments for notes payable | -$1.5M | -$7.8M |
| Proceeds from warrant exercises | $2.5M | |
| Stock option exercises | $889.0K | $177.0K |
| Net cash provided by financing activities | $20.1M | $9.6M |
| Effect of exchange rate changes on cash | $37.0K | -$9.0K |
| Net increase in cash | $10.2M | $367.0K |
| Cash paid for interest | $22.0K | $11.0K |
| Cash paid for taxes | $100.0K | $11.0K |
| Recognition of Right-of-use assets and related lease liabilities upon lease amendment | $1.8M | |
| Tenant improvement allowance payments made by the lessor directly to a third party | -$327.0K | |
| Issuance of common stock to settle accounts and notes payable | $1.2M | $3.2M |
| Short-term financing of insurance premium | -$580.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Spectral AI, Inc. sits at the top of its group. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Spectral AI, Inc.
- LMR Partners LLP Filed SCHEDULE 13G on Spectral AI, Inc., latest Aug 14, 2026
- Hudson Bay Capital Management LP Filed SCHEDULE 13G/A on Spectral AI, Inc., latest May 8, 2026 (2 filings since Feb 11, 2026)
- Erich Spangenberg Filed SCHEDULE 13D/A on Spectral AI, Inc., latest Mar 18, 2026 (4 filings since Sep 27, 2023)
- Laurence E. Hirsch Filed SCHEDULE 13G/A on Spectral AI, Inc., latest Aug 14, 2025 (3 filings since Nov 3, 2023)
- Octopus Investments Filed SC 13G/A on Spectral AI, Inc., latest Nov 14, 2024 (2 filings since Feb 8, 2024)
- John Michael Dimaio Filed SC 13D/A on Spectral AI, Inc., latest Feb 27, 2024 (3 filings since Sep 21, 2023)
- Beryl Capital Management LLC Filed SC 13G/A on Spectral AI, Inc., latest Feb 14, 2023 (2 filings since Dec 8, 2022)
- GLAZER CAPITAL, LLC Filed SC 13G/A on Spectral AI, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Saba Capital Management, L.P. Filed SC 13G/A on Spectral AI, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Rosecliff Acquisition Sponsor I LLC Filed SC 13G on Spectral AI, Inc., latest Feb 14, 2022
- Spectral AI, Inc. Dallas, Texas
- Spectral Deepview Limited Subsidiary · Ireland
- Spectral MD Holdings LLC Subsidiary · Delaware, United States
- Spectral MD UK Limited Subsidiary · United Kingdom
- Spectral MD, Inc. Subsidiary · Delaware, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Spectral AI, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $258.0K5 Dec 31, 2025 | $2.0K5 Dec 31, 2024 | +12800.0% |
| Operating-lease assets (leased space) | $1.4M5 Dec 31, 2025 | $2.0M5 Dec 31, 2024 | −28.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $15.4M5 Dec 31, 2025 | $5.2M7 Dec 31, 2024 | +196.2% |
Inventory
Properties, in its own words
We currently maintain our executive offices, which are located at 2515 McKinney Avenue, Suite 1000, Dallas, TX 75201. The cost for this space is approximately $105,000 per month. We also maintain an office space in the United Kingdom at Orion House, Bessemer Road, Welwyn Garden City, Herts Al7 1HH. The cost for this space is $14,000 per month. We consider our current office space adequate for our current operations.
Item 2 of the 10-K filed Mar 25, 2026.4
Leadership
Who has led Spectral AI, Inc., and when. Pick a name to see everywhere that person has worked.
President
Chief financial officer
Chief operating officer
- Chief executive officerVincent S. Capone Apr 6, 2026 to now12
- Chief executive officerPeter M. Carlson May 13, 2024 to May 13, 202413
- Chief executive officerWensheng Fan Sep 13, 2023 to Sep 13, 202314
- PresidentJordan Zimmerman Feb 11, 2021 to Feb 11, 202115
- Chief financial officerVincent S. Capone May 13, 2024 to now16
- Chief financial officerNils Windler Sep 13, 2023 to Sep 13, 202317
- Chief financial officerKieran Goodwin Feb 11, 2021 to Feb 11, 202118
- Chief operating officerStan Micek May 14, 2024 to May 14, 202419
- Chief operating officerNikolaos Pagoulatos Sep 13, 2023 to Sep 13, 202320
Board members and other officers (16)
- Chief Commerical OfficerJeremiah A. Sparks May 13, 2024 to May 13, 202421
- CHIEF SCIENTISTJeffrey Edward Thatcher Sep 14, 2023 to Sep 14, 202322
- Board memberMarion Ann Snyder Apr 27, 2026 to now23
- Board memberDeepak Sadagopan May 20, 2026 to now24
- Board memberErich Spangenberg May 13, 2024 to May 17, 202425
- Board memberPeter M. Carlson May 13, 2024 to May 13, 202413
- Board memberMartin C.b. Mellish Sep 13, 2023 to now26
- Board memberRichard John Cotton Sep 13, 2023 to now27
- Board memberWensheng Fan Sep 13, 2023 to Sep 13, 202314
- Board memberXiaojia Cynthia Cai Sep 13, 2023 to Sep 13, 202328
- Board memberBrian J. Radecki Feb 11, 2021 to Sep 13, 202329
- Board memberFranklin S. Edmonds Jr. Feb 11, 2021 to Sep 13, 202330
- Board memberHeather Bellini Feb 11, 2021 to Sep 13, 202331
- Board memberJordan Zimmerman Feb 11, 2021 to Feb 11, 202115
- Board memberKieran Goodwin Feb 11, 2021 to Feb 11, 202118
- General counselVincent S. Capone Sep 13, 2023 to now32
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Spectral Deepview Limited Ireland3
- Spectral MD Holdings LLC Delaware3
- Spectral MD UK Limited United Kingdom3
- Spectral MD, Inc. Delaware3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Rosecliff Acquisition Corp IDec 23, 2020 to Sep 13, 20232
Timeline
- Sep 15, 20268-K Regulation FD disclosure33
- Aug 12, 20268-K Results of operations; Regulation FD disclosure34
- Jul 8, 20268-K Executive or director change; Regulation FD disclosure35
- Jun 1, 20268-K Shareholder vote; Regulation FD disclosure36
- May 26, 20268-K Regulation FD disclosure37
- Apr 22, 20268-K Executive or director change38
- Apr 8, 20268-K Executive or director change; Regulation FD disclosure39
- Apr 6, 2026New chief executive Vincent S. Capone becomes CEO12
- Mar 25, 20268-K Results of operations; Regulation FD disclosure40
- Mar 20, 20268-K Regulation FD disclosure41
- Feb 10, 20268-K Executive or director change; Regulation FD disclosure42
- Feb 3, 20268-K Executive or director change43
- Jan 6, 20268-K Executive or director change44
- May 13, 2024New chief executive Peter M. Carlson becomes CEO13
- Sep 13, 2023New chief executive Wensheng Fan becomes CEO14
Calendar
Coming up
- Nov 10, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.13) a share, on Nov 11, 2025.45
When it reported results
- Aug 12, 2026Reported quarterly or annual results34
- Mar 25, 2026Reported quarterly or annual results40
- Aug 13, 2025Reported quarterly or annual results46
- May 14, 2025Reported quarterly or annual results47
- Apr 2, 2025Reported quarterly or annual results48
- Mar 29, 2024Reported quarterly or annual results49
- Nov 14, 2023Reported quarterly or annual results50
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
263 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 55 insider forms, 22 large holders, 104 other. The latest 20:
- Sep 29, 20264 EDGAR
- Sep 25, 20264 EDGAR
- Sep 21, 20264 EDGAR
- Sep 15, 20268-K CURRENT REPORT EDGAR
- Sep 14, 20264 EDGAR
- Aug 17, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 12, 20268-K CURRENT REPORT EDGAR
- Aug 11, 202610-Q QUARTERLY REPORT EDGAR
- Jul 8, 20268-K CURRENT REPORT EDGAR
- Jun 29, 20264 EDGAR
- Jun 1, 20268-K CURRENT REPORT EDGAR
- Jun 1, 20264 EDGAR
- May 27, 20264 EDGAR
- May 26, 20268-K CURRENT REPORT EDGAR
- May 20, 20264 EDGAR
- May 18, 20264 EDGAR
- May 18, 20264 EDGAR
- May 13, 202610-Q QUARTERLY REPORT EDGAR
- May 8, 2026SCHEDULE 13G/A EDGAR
The 263 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 10, 2024 | DiMaio John MichaelDirector | Buy | 6,000 | $1.72 | $10.3K | Form 4 |
| Nov 20, 2023 | DiMaio John MichaelDirector | Buy | 2,000 | $2.67 | $5.3K | Form 4 |
| Nov 16, 2023 | DiMaio John MichaelDirector | Buy | 500 | $2.68 | $1.3K | Form 4 |
| Nov 14, 2023 | DiMaio John MichaelDirector | Buy | 355 | $2.81 | $998 | Form 4 |
| Sep 13, 2023 | DiMaio John MichaelDirector | Buy | 198 | $5.07 | $1.0K | Form 4 |
| Sep 12, 2023 | DiMaio John MichaelDirector | Buy | 1,000 | $5.97 | $6.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- LMR Partners LLPSCHEDULE 13G, 1 filing Aug 14, 202651
- Hudson Bay Capital Management LPSCHEDULE 13G/A, 2 filings Feb 11, 2026 to May 8, 202652
- Erich SpangenbergSCHEDULE 13D/A, 4 filings Sep 27, 2023 to Mar 18, 202653
- Laurence E. HirschSCHEDULE 13G/A, 3 filings Nov 3, 2023 to Aug 14, 202554
- Octopus InvestmentsSC 13G/A, 2 filings Feb 8, 2024 to Nov 14, 202455
- John Michael DimaioSC 13D/A, 3 filings Sep 21, 2023 to Feb 27, 202456
- Beryl Capital Management LLCSC 13G/A, 2 filings Dec 8, 2022 to Feb 14, 202357
- GLAZER CAPITAL, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202358
- Saba Capital Management, L.P.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202359
- Rosecliff Acquisition Sponsor I LLCSC 13G, 1 filing Feb 14, 202260
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Vincent Capone | 59 | $440.0K | $1.0M61 |
| 2025 | Stan Micek | 64 | $360.0K | $468.0K61 |
| 2025 | John Michael DiMaio | $200.0K | $407.5K61 | |
| 2024 | Chief Executive Officer and Former Chief Financial Officer and General Counsel | $400.0K | $987.5K61 | |
| 2024 | Chief Operating Officer | $270.0K61 | ||
| 2024 | Former PrincipalExecutive Officer | $67.5K | $95.8K61 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 994,410 | $1.7M | 0.0% | +268,120 |
| Highlander Partners, L.P. | 900,000 | $1.6M | 0.5% | No change |
| Marshall Wace, Llp | 827,454 | $1.4M | 0.0% | New |
| Bridgeway Capital Management, LLC | 287,000 | $496.5K | 0.0% | +88,000 |
| Jane Street Group, LLC | 226,319 | $391.5K | 0.0% | +5,318 |
| UBS Group AG | 225,823 | $390.7K | 0.0% | +112,803 |
| Geode Capital Management, LLC | 222,595 | $385.2K | 0.0% | −78,612 |
| BlackRock, Inc. | 161,777 | $279.9K | 0.0% | +39,523 |
| LPL Financial LLC | 160,701 | $278.0K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 142,664 | $246.8K | 0.0% | +868 |
| University Of Texas/texas Am Investment Management Co | 121,711 | $210.6K | 0.0% | −88,777 |
| Rathbones Group PLC | 87,045 | $150.6K | 0.0% | −87,045 |
| State Street Corp | 75,600 | $130.8K | 0.0% | No change |
| Forum Financial Management, LP | 60,501 | $104.7K | 0.0% | No change |
| Northern Trust Corp | 50,547 | $87.4K | 0.0% | +18,449 |
| XTX Topco Ltd | 32,927 | $57.0K | 0.0% | +5,839 |
| N.E.W. Advisory Services LLC | 20,010 | $34.6K | 0.0% | +6,010 |
| Jpmorgan Chase & Co | 20,259 | $34.2K | 0.0% | New |
| StoneX Group Inc. | 15,343 | $31.6K | 0.0% | New |
| Royal Bank Of Canada | 15,452 | $27.0K | 0.0% | New |
| Morgan Stanley | 13,799 | $23.9K | 0.0% | +5,405 |
| Raymond James Financial Inc | 12,800 | $22.1K | 0.0% | No change |
| Tower Research Capital LLC (TRC) | 12,121 | $21.0K | 0.0% | New |
| Philip James Wealth Mangement, LLC | 12,000 | $20.8K | 0.0% | No change |
| Engineers Gate Manager LP | 11,046 | $19.1K | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Spectral AI, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARSpectral AI, Inc.1
- CIK0001833498
- Employer ID (EIN)85-39871484
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address2515 Mckinney Ave #1000, Dallas, TX 752011
- Phone(212) 492-30001
- Shares outstanding32,184,928 as of Aug 11, 202610
- Public float$72.0M as of Jun 30, 20254
- AuditorForvis Mazars, LLP, Dallas, Texas PCAOB ID 686; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceDec 23, 20201
- Filings299 in all: 8-K (65), 4 (52), 425 (27), 3 (18), 10-Q (17), CORRESP (16), UPLOAD (13), EFFECT (8)1
All 38 form types
SC 13G (8), 424B3 (7), SC 13G/A (6), 10-K (5), 424B5 (5), S-1/A (5), DEF 14A (4), S-1 (4), S-3 (4), S-4/A (4), DEFA14A (3), SC 13D/A (3), NT 10-Q (2), PRE 14A (2), S-3/A (2), S-8 (2), SC 13D (2), SCHEDULE 13G (2), SCHEDULE 13G/A (2), 144 (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), PRER14A (1), S-1MEF (1), S-4 (1), SCHEDULE 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 25, 2026
Quarterly report (10-Q) Aug 11, 2026
Proxy statement (DEF 14A) Apr 16, 2026
Latest 8-K (8-K) Sep 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.0001 per share | MDAI | Nasdaq |
| Redeemable warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $2.75 | MDAIW | Nasdaq |
From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).4
Risk factors and legal proceedings
Legal proceedings
The Company is not a party to any material legal proceedings or pending claims. The Company is aware of a material threatened claim that it believes is without merit. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. To our knowledge, there is not any material legal proceeding threatened against any of our officers or directors in their corporate capacity.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC EDGARJordan Zimmerman, President
- 16
- 17
- 18
- 19SEC EDGARStan Micek, Chief operating officer
- 20
- 21
- 22
- 23SEC EDGARMarion Ann Snyder, Board member
- 24SEC EDGARDeepak Sadagopan, Board member
- 25SEC EDGARErich Spangenberg, Board member
- 26SEC EDGARMartin C.b. Mellish, Board member
- 27SEC EDGARRichard John Cotton, Board member
- 28SEC EDGARXiaojia Cynthia Cai, Board member
- 29SEC EDGARBrian J. Radecki, Board member
- 30
- 31SEC EDGARHeather Bellini, Board member
- 32SEC EDGARVincent S. Capone, General counsel
- 33SEC EDGARRegulation FD disclosure
- 34
- 35
- 36
- 37SEC EDGARRegulation FD disclosure
- 38SEC EDGARExecutive or director change
- 39
- 40
- 41SEC EDGARRegulation FD disclosure
- 42
- 43SEC EDGARExecutive or director change
- 44SEC EDGARExecutive or director change
- 45NasdaqNasdaq calendar
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61